How to read the figures
Every substance on this page gets the same four steps, so they can be compared on equal terms. Press play, drag the slider, or jump to a step.
- The way in. How it reaches the blood and the brain, and what the body changes on the way.
- The target, up close. A synapse, the gap where one nerve cell signals to the next, and what the substance does there.
- The brain during. What brain scans have shown while it acts. Where no scans exist, the map stays blank rather than guessed.
- How long it lasts. One shared time scale, from seconds to a month, and what follows.
This page explains; it does not recommend. Several of these substances can kill, alone or combined, and some withdrawals need medical care. If you are struggling with any of them, talk to our intake team or your doctor.
Compare any two
Choose two substances. Both play on the same clock and the same time scale.
Side by side, in motion
Pick any two
Step 4 · How long it lastsIboga. The ceremony runs until sunrise, about twelve hours, then a day of processing. Noribogaine leaves slowly, with a half-life of 28 to 49 hours (Glue et al., 2015), one reason the heart is watched after the night.5-MeO-DMT. Inhaled, the main effects last about fifteen to twenty minutes (Reckweg et al., 2022). Combining it with an MAO inhibitor, such as ayahuasca’s vine, is considered dangerous.
At a glance
| Substance | Main target | How long | What follows |
|---|---|---|---|
| Iboga | NMDA, kappa opioid, SERT and more | About 12 h, then a processing day | Noribogaine stays for days |
| Ibogaine | NMDA, kappa opioid, SERT and more | A day or more | Slower brain rhythms days later (one study) |
| Psilocybin | Serotonin 5-HT2A | About 4 to 6 h | Brain networks more integrated in depression trials |
| LSD | Serotonin 5-HT2A | Up to about 12 h | Cleared within a day |
| Ayahuasca (DMT) | Serotonin 5-HT2A | About 4 h | Cleared within hours |
| 5-MeO-DMT | Serotonin 5-HT1A and 5-HT2A | About 15 to 20 min | Cleared quickly |
| MDMA | Serotonin transporter, run in reverse | About 3 to 6 h | Low mood for some, days later |
| Ketamine | NMDA receptor channel | About 1 h | Mood lift for days in some depression trials |
| Cannabis | CB1 receptors | About 2 to 4 h smoked | Detectable for weeks in daily users |
| Cocaine | Dopamine transporter, blocked | About 15 to 30 min snorted | Crash and craving |
| Amphetamines | Dopamine transporter, run in reverse | Many hours | Transporters reduced in heavy users |
| Nicotine | Nicotinic receptors (α4β2) | Minutes; half-life about 2 h | More receptors, steady craving |
| Opioids | Mu opioid receptors | A few hours (short-acting) | Withdrawal; overdose risk when tolerance drops |
| Kratom | Mu opioid receptors (partial) | A few hours | Dependence with daily use |
| Alcohol | GABA-A (up), NMDA (down) | Hours, by amount | Withdrawal can be dangerous |
| Benzodiazepines | GABA-A receptors (side site) | Hours to days | Withdrawal can cause seizures |
Iboga and ibogaine
The same molecule in two forms: the whole root bark in ceremony, or the purified alkaloid in a clinic.
Iboga Many targets, and it stays for days
The root bark of Tabernanthe iboga, a shrub of Central Africa, taken in ceremony in the Bwiti tradition of Gabon. Its main alkaloid is ibogaine, and the bark carries several others. Iboga root bark, explained
Step 4 · How long it lastsThe ceremony runs until sunrise, about twelve hours, then a day of processing. Noribogaine leaves slowly, with a half-life of 28 to 49 hours (Glue et al., 2015), one reason the heart is watched after the night.
Ibogaine The same molecule, purified
Ibogaine hydrochloride is the single alkaloid extracted from iboga, given in clinics as a measured dose by body weight, usually with heart monitoring. Iboga vs ibogaine: retreat or clinic?
Step 4 · How long it lastsIn veterans recorded about three and a half days after magnesium-ibogaine treatment, brain waves had shifted toward slower theta and alpha rhythms, and the shift tracked better self-control on tests (Lissemore et al., 2025).
Classic psychedelics
Psilocybin, LSD, DMT and 5-MeO-DMT all work through serotonin receptors, but differ in how long they last and which receptor they favor.
Psilocybin Magic mushrooms, about six hours
Psilocybin is the active compound of so-called magic mushrooms, mostly Psilocybe species, and the most studied psychedelic in current clinical trials. Iboga vs psilocybin, ketamine and MDMA
Step 4 · How long it lastsThe effects last about four to six hours. In depression trials, brain networks were more integrated after psilocybin therapy, and the change tracked improvement (Daws et al., 2022).
LSD The same receptor, held for longer
Lysergic acid diethylamide, made in a lab from a compound of the ergot fungus, and active at doses of millionths of a gram. How psychedelics compare
Step 4 · How long it lastsEffects last up to about twelve hours, and LSD's half-life in the blood was about two and a half hours (Dolder et al., 2017).
Ayahuasca (DMT) One main target, gone within hours
A brew from the Amazon, usually of the Banisteriopsis caapi vine and Psychotria viridis leaves. The leaves bring DMT; the vine lets it work when swallowed. Iboga vs ayahuasca
Step 4 · How long it lastsEffects peak at one and a half to two hours (Riba et al., 2003) and generally pass within about four. Because of the MAO block, ayahuasca can interact dangerously with antidepressants.
5-MeO-DMT Seconds to arrive, minutes to pass
5-methoxy-N,N-dimethyltryptamine, a compound found in some plants and in the secretion of the Sonoran Desert toad. Ibogaine and 5-MeO-DMT vs an iboga retreat
Step 4 · How long it lastsInhaled, the main effects last about fifteen to twenty minutes (Reckweg et al., 2022). Combining it with an MAO inhibitor, such as ayahuasca’s vine, is considered dangerous.
MDMA and ketamine
Often grouped with psychedelics, they work in quite different ways: one floods serotonin, the other blocks a glutamate channel.
MDMA Runs the serotonin pump backwards
3,4-methylenedioxymethamphetamine, known as ecstasy or molly, an amphetamine relative with strong serotonin effects. Iboga vs psilocybin, ketamine and MDMA
Step 4 · How long it lastsMain effects last about three to six hours. Some people describe low mood in the days after. Overheating and drinking too much water are among its acute dangers.
Ketamine Plugs a glutamate channel
A dissociative anesthetic used in hospitals since the 1970s, and since 2019 as an esketamine nasal spray for depression. Iboga for ketamine addiction
Step 4 · How long it lastsMain effects pass within about an hour. In a trial for treatment-resistant depression, one infusion lifted mood within hours, and in about a third the effect lasted at least a week (Zarate et al., 2006). Frequent heavy use can damage the bladder.
Cannabis
A receptor system of its own, spread through memory and movement areas.
Cannabis Turns down the sending side
The cannabis plant. Its main intoxicating compound is THC (delta-9-tetrahydrocannabinol); CBD, another compound in the plant, is not intoxicating. Iboga for cannabis addiction
Step 4 · How long it lastsSmoked, effects last about two to four hours; eaten, longer. THC is stored in body fat, so in daily users it can be detected for weeks.
Stimulants
Three ways to push dopamine up: block its pump, reverse its pump, or switch on the neurons that release it.
Cocaine Blocks the dopamine pump
A stimulant made from the leaves of the coca plant. Iboga for cocaine addiction
Step 4 · How long it lastsSnorted, the high lasts roughly fifteen to thirty minutes, then a crash and craving. People who used cocaine heavily had fewer dopamine D2 receptors in the striatum, linked to lower activity in the front of the brain, and the deficit persisted three to four months after detox (Volkow et al., 1993).
Amphetamines Meth and Adderall: the pump in reverse
Amphetamine, in prescription pills such as Adderall, and methamphetamine, a stronger and more harmful relative. Iboga for Adderall addiction
Step 4 · How long it lastsMethamphetamine's effects last many hours. In five people who had used it heavily, dopamine transporters were reduced and partly recovered after about a year or more without the drug (Volkow et al., 2001).
Nicotine Seconds to the brain, every puff
The addictive compound in tobacco and in vapes. Iboga to quit smoking
Step 4 · How long it lastsNicotine's half-life is about two hours, so cravings return within hours. Regular use leaves the brain with more nicotinic receptors than before (Benowitz, 2009).
Opioids and depressants
Substances that slow the brain down, and the ones whose withdrawal can be medically dangerous.
Opioids Heroin, fentanyl, painkillers
Drugs from the opium poppy and their synthetic relatives, from prescription painkillers to heroin and fentanyl. Iboga for opioid addiction
Step 4 · How long it lastsShort-acting opioids wear off in a few hours. After daily use, withdrawal follows, with aching, sweating, diarrhea and strong craving. Tolerance falls quickly after stopping, so a former dose can kill.
Kratom A partial opioid from a leaf
Leaves of Mitragyna speciosa, a tree of Southeast Asia. Iboga for kratom addiction
Step 4 · How long it lastsEffects last a few hours. Daily use can lead to dependence, and stopping brings a withdrawal that resembles a milder opioid withdrawal.
Alcohol Presses the brake, eases the accelerator
Ethanol, the alcohol in beer, wine and spirits. Iboga for alcohol addiction
Step 4 · How long it lastsEffects last as long as alcohol stays in the blood, hours. In people who are dependent, stopping suddenly can cause dangerous withdrawal with tremor, seizures and delirium, so detox needs medical care.
Benzodiazepines Xanax, Valium, Klonopin
Prescription sedatives such as alprazolam (Xanax), diazepam (Valium) and clonazepam (Klonopin). Iboga for benzodiazepine addiction
Step 4 · How long it lastsSome last hours, others, like diazepam, days. After regular use, stopping suddenly can trigger seizures, so tapering under medical care is needed. With opioids or alcohol, breathing can stop.
Where iboga differs
Most substances on this page work through one main target and are gone within hours. Iboga touches several systems at once, and its metabolite noribogaine stays for days. That is why it is studied for addiction, and also why it needs medical screening, heart monitoring and an experienced team. Read how iboga works, the research, study by study, or how we keep the ceremony safe.
Sources
- Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology 2015;55(2):189–194. Read ↗
- Luciano DJ, Della Sera EA, Jethmal EG. Neurologic, electroencephalographic and general medical observations in subjects administered ibogaine. MAPS Bulletin 1999/2000;9(4):27–30. Five subjects; two had EEGs recorded during ibogaine intoxication. A bulletin report, not a peer-reviewed study. Read ↗
- Glue P, Winter H, Garbe K, et al. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology 2015;55(6):680–687. Read ↗
- Lissemore JI, Chaiken A, Cherian KN, et al. Magnesium–ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury. Nature Mental Health 2025;3(8):918–931. Read ↗
- Sridhar M, Azeez A, Geoly AD, et al. Neural correlates of ibogaine: evidence from functional neuroimaging of military veterans. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2026;11(6):624–633. Scans before, immediately after and one month after treatment. Read ↗
- González J, Cavelli M, Castro-Zaballa S, et al. EEG gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine in the rat. ACS Pharmacology & Translational Science 2021;4(2):517–525. Read ↗
- Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS 2012;109(6):2138–2143. Read ↗
- Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine 2022;28(4):844–851. Read ↗
- Wacker D, Wang S, McCorvy JD, et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 2017;168(3):377–389. Read ↗
- Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. PNAS 2016;113(17):4853–4858. Read ↗
- Dolder PC, Schmid Y, Steuer AE, et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clinical Pharmacokinetics 2017;56(10):1219–1230. Read ↗
- de Araujo DB, Ribeiro S, Cecchi GA, et al. Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion. Human Brain Mapping 2012;33(11):2550–2560. Read ↗
- Palhano-Fontes F, Andrade KC, Tofoli LF, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLOS ONE 2015;10(2):e0118143. Read ↗
- Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 2003;306(1):73–83. Read ↗
- Reckweg JT, Uthaug MV, Szabo A, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). Journal of Neurochemistry 2022;162(1):128–146. Read ↗
- Carhart-Harris RL, Murphy K, Leech R, et al. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biological Psychiatry 2015;78(8):554–562. Read ↗
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006;63(8):856–864. Read ↗
- Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. PNAS 1990;87(5):1932–1936. Read ↗
- Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386(6627):827–830. Read ↗
- Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14(2):169–177. Read ↗
- Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. Journal of Neuroscience 2001;21(23):9414–9418. Read ↗
- Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annual Review of Pharmacology and Toxicology 2009;49:57–71. Read ↗
- Pattinson KTS. Opioids and the control of respiration. British Journal of Anaesthesia 2008;100(6):747–758. Read ↗
- Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. Journal of the American Chemical Society 2016;138(21):6754–6764. Read ↗
- Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003;49(4):226–231. Read ↗
- Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner Journal 2013;13(2):214–223. Read ↗